QuantHealth, a Tel Aviv-based company that builds AI software for simulating clinical trials, has raised a $45 million Series B led by Qumra Capital, according to Cailey Gleeson of Fierce Healthcare, whose report was surfaced by Techmeme. The round brings the company's total funding to roughly $70 million.
The pitch behind clinical trial simulation is straightforward, even if the underlying math is not. Drug trials are among the slowest and most expensive steps in bringing a medicine to market, and most drug candidates that enter human testing never reach approval. Simulation software aims to model how a trial might play out — which patients to enroll, at what doses, with what likely outcomes — before a company commits to running the real thing. Fierce Healthcare describes QuantHealth as using artificial intelligence to power that modeling.
The funding details available so far are limited to the headline numbers: $45 million in this round, Qumra Capital in the lead, and about $70 million raised in total. The source item does not specify the company's valuation, its customer roster, how many trials its software has modeled, or which other investors participated alongside Qumra. Nor does it detail how QuantHealth's models are trained or validated — questions that tend to matter a great deal to the pharmaceutical companies and regulators who would ultimately rely on such predictions.
What the round does signal is investor appetite for AI applied to the unglamorous middle of the drug pipeline. Much of the attention in AI-for-biology has gone to molecule discovery — finding promising compounds in the first place. Trial design sits further downstream, where the costs are largest and the failures most painful.
Why it matters: if software can reliably flag a trial that is destined to fail before hundreds of millions of dollars and years of patient enrollment are spent on it, the savings land not just on drugmakers' balance sheets but on the timeline for getting working medicines to the people waiting for them.